Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 283

1.

Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.

Tao YX, Conn PM.

Physiol Rev. 2018 Apr 1;98(2):697-725. doi: 10.1152/physrev.00029.2016. Review.

2.

Pharmacoperone rescue of vasopressin 2 receptor mutants reveals unexpected constitutive activity and coupling bias.

Janovick JA, Spicer TP, Bannister TD, Scampavia L, Conn PM.

PLoS One. 2017 Aug 2;12(8):e0181830. doi: 10.1371/journal.pone.0181830. eCollection 2017.

3.

Drug Library Screening for the Identification of Ionophores That Correct the Mistrafficking Disorder Associated with Oxalosis Kidney Disease.

Hou S, Madoux F, Scampavia L, Janovick JA, Conn PM, Spicer TP.

SLAS Discov. 2017 Aug;22(7):887-896. doi: 10.1177/2472555217689992. Epub 2017 Jan 31.

PMID:
28346094
4.

Receptor antagonism/agonism can be uncoupled from pharmacoperone activity.

Janovick JA, Spicer TP, Smith E, Bannister TD, Kenakin T, Scampavia L, Conn PM.

Mol Cell Endocrinol. 2016 Oct 15;434:176-85. doi: 10.1016/j.mce.2016.07.003. Epub 2016 Jul 4.

5.

Identification of Potential Pharmacoperones Capable of Rescuing the Functionality of Misfolded Vasopressin 2 Receptor Involved in Nephrogenic Diabetes Insipidus.

Smith E, Janovick JA, Bannister TD, Shumate J, Scampavia L, Conn PM, Spicer TP.

J Biomol Screen. 2016 Sep;21(8):824-31. doi: 10.1177/1087057116653925. Epub 2016 Jun 8.

6.
7.

Measurement of Blood Volume in Adult Rhesus Macaques (Macaca mulatta).

Hobbs TR, Blue SW, Park BS, Greisel JJ, Conn PM, Pau FK.

J Am Assoc Lab Anim Sci. 2015 Nov;54(6):687-93.

8.

Assay strategies for identification of therapeutic leads that target protein trafficking.

Conn PM, Spicer TP, Scampavia L, Janovick JA.

Trends Pharmacol Sci. 2015 Aug;36(8):498-505. doi: 10.1016/j.tips.2015.05.004. Epub 2015 Jun 8. Review.

9.

Pharmacoperones: targeting therapeutics toward diseases caused by protein misfolding.

Ulloa-Aguirre A, Zariñán T, Conn PM.

Rev Invest Clin. 2015 Jan-Feb;67(1):15-9.

10.

Development of a phenotypic high-content assay to identify pharmacoperone drugs for the treatment of primary hyperoxaluria type 1 by high-throughput screening.

Madoux F, Janovick JA, Smithson D, Fargue S, Danpure CJ, Scampavia L, Chen YT, Spicer TP, Conn PM.

Assay Drug Dev Technol. 2015 Jan-Feb;13(1):16-24. doi: 10.1089/adt.2014.627.

PMID:
25710543
11.

Gonadotrope-specific deletion of Dicer results in severely suppressed gonadotropins and fertility defects.

Wang H, Graham I, Hastings R, Gunewardena S, Brinkmeier ML, Conn PM, Camper SA, Kumar TR.

J Biol Chem. 2015 Jan 30;290(5):2699-714. doi: 10.1074/jbc.M114.621565. Epub 2014 Dec 18.

12.

A phenotypic high throughput screening assay for the identification of pharmacoperones for the gonadotropin releasing hormone receptor.

Conn PM, Smith E, Spicer T, Chase P, Scampavia L, Janovick JA.

Assay Drug Dev Technol. 2014 May;12(4):238-46. doi: 10.1089/adt.2014.576.

13.

Redirecting intracellular trafficking and the secretion pattern of FSH dramatically enhances ovarian function in mice.

Wang H, Larson M, Jablonka-Shariff A, Pearl CA, Miller WL, Conn PM, Boime I, Kumar TR.

Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5735-40. doi: 10.1073/pnas.1321404111. Epub 2014 Mar 31.

14.

Quality control autophagy degrades soluble ERAD-resistant conformers of the misfolded membrane protein GnRHR.

Houck SA, Ren HY, Madden VJ, Bonner JN, Conlin MP, Janovick JA, Conn PM, Cyr DM.

Mol Cell. 2014 Apr 10;54(1):166-179. doi: 10.1016/j.molcel.2014.02.025. Epub 2014 Mar 27.

15.

Chaperoning G protein-coupled receptors: from cell biology to therapeutics.

Tao YX, Conn PM.

Endocr Rev. 2014 Aug;35(4):602-47. doi: 10.1210/er.2013-1121. Epub 2014 Mar 24. Review.

16.

Preface. Endosome signaling part B.

Conn PM.

Methods Enzymol. 2014;535:xxi. doi: 10.1016/B978-0-12-397925-4.10000-8. No abstract available.

PMID:
24377938
17.

Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens.

Conn PM, Smithson DC, Hodder PS, Stewart MD, Behringer RR, Smith E, Ulloa-Aguirre A, Janovick JA.

Pharmacol Res. 2014 May;83:38-51. doi: 10.1016/j.phrs.2013.12.004. Epub 2013 Dec 25. Review.

18.

Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy.

Janovick JA, Stewart MD, Jacob D, Martin LD, Deng JM, Stewart CA, Wang Y, Cornea A, Chavali L, Lopez S, Mitalipov S, Kang E, Lee HS, Manna PR, Stocco DM, Behringer RR, Conn PM.

Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21030-5. doi: 10.1073/pnas.1315194110. Epub 2013 Dec 9.

19.

"Pharmacoperone": what's in a word?

Conn PM, Ulloa-Aguirre A, Janovick JA.

Pharmacol Res. 2014 May;83:1-2. doi: 10.1016/j.phrs.2013.11.005. Epub 2013 Nov 20. Review. No abstract available.

PMID:
24269962
20.

Methods in Cell Biology. Receptor-receptor interactions. Preface.

Conn PM.

Methods Cell Biol. 2013;117:xxi-xxii. doi: 10.1016/B978-0-12-408143-7.10000-3. No abstract available.

PMID:
24143993
21.

Species sequence differences determine the interaction of GnRH receptor with the cellular quality control system.

Cabrera-Wrooman A, Janovick JA, Conn PM.

Mol Cell Endocrinol. 2013 Dec 5;381(1-2):1-7. doi: 10.1016/j.mce.2013.07.012. Epub 2013 Jul 24.

22.

Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function.

Ulloa-Aguirre A, Zariñán T, Dias JA, Conn PM.

Mol Cell Endocrinol. 2014 Jan 25;382(1):411-423. doi: 10.1016/j.mce.2013.06.024. Epub 2013 Jun 24. Review.

23.

High-throughput screen for pharmacoperones of the vasopressin type 2 receptor.

Conn PM, Smith E, Hodder P, Janovick JA, Smithson DC.

J Biomol Screen. 2013 Sep;18(8):930-7. doi: 10.1177/1087057113483559. Epub 2013 May 2.

24.

Methods in Enzymology. G protein coupled receptors trafficking and oligomerization. Preface.

Conn PM.

Methods Enzymol. 2013;521:xix. doi: 10.1016/B978-0-12-391862-8.10000-6. No abstract available.

PMID:
23351751
25.

Therapeutic rescue of misfolded/mistrafficked mutants: automation-friendly high-throughput assays for identification of pharmacoperone drugs of GPCRs.

Smithson DC, Janovick JA, Conn PM.

Methods Enzymol. 2013;521:3-16. doi: 10.1016/B978-0-12-391862-8.00001-6.

PMID:
23351731
26.

Preface.

Conn PM.

Methods Enzymol. 2013;520:xvii. doi: 10.1016/B978-0-12-391861-1.10000-0. No abstract available.

PMID:
23332709
27.

Preface: Laboratory methods in cell biology.

Conn PM.

Methods Cell Biol. 2013;113:xv. doi: 10.1016/B978-0-12-407239-8.22001-6. No abstract available.

PMID:
23317913
28.

The role of scientists and clinicians in raising public support for animal research in reproductive biology and medicine.

Dancet EA, Brännström M, Brasky K, Chai D, Chan AW, Conn PM, Else J, Falconer H, Fazleabas AT, Farah IO, Goddeeris BM, Golos TG, Hau J, Hearn JP, Kariuki TM, Kyama CM, Lebovic DI, Mwenda JM, Ndung'u J, Nyachieo A, Parker J, Slayden OD, Stouffer RL, Strauss JF, Taylor HS, Vanderpoel S, Westergaard JG, Zelinski M, D'Hooghe TM.

Biol Reprod. 2013 Feb 7;88(2):33. doi: 10.1095/biolreprod.112.105908. Print 2013 Feb. No abstract available.

PMID:
23255340
29.

Gonadotropin-releasing hormone receptor activates GTPase RhoA and inhibits cell invasion in the breast cancer cell line MDA-MB-231.

Aguilar-Rojas A, Huerta-Reyes M, Maya-Núñez G, Arechavaleta-Velásco F, Conn PM, Ulloa-Aguirre A, Valdés J.

BMC Cancer. 2012 Nov 23;12:550. doi: 10.1186/1471-2407-12-550.

30.

Pharmacological chaperones correct misfolded GPCRs and rescue function: protein trafficking as a therapeutic target.

Maya-Núñez G, Ulloa-Aguirre A, Janovick JA, Conn PM.

Subcell Biochem. 2012;63:263-89. doi: 10.1007/978-94-007-4765-4_14. Review.

PMID:
23161143
31.

Mice harboring Gnrhr E90K, a mutation that causes protein misfolding and hypogonadotropic hypogonadism in humans, exhibit testis size reduction and ovulation failure.

Stewart MD, Deng JM, Stewart CA, Mullen RD, Wang Y, Lopez S, Serna MK, Huang CC, Janovick JA, Pask AJ, Schwartz RJ, Conn PM, Behringer RR.

Mol Endocrinol. 2012 Nov;26(11):1847-56. doi: 10.1210/me.2012-1072. Epub 2012 Aug 23.

32.

Rescue of misrouted GnRHR mutants reveals its constitutive activity.

Janovick JA, Pogozheva ID, Mosberg HI, Cornea A, Conn PM.

Mol Endocrinol. 2012 Jul;26(7):1179-88. doi: 10.1210/me.2012-1089. Epub 2012 May 17.

33.

Methods in Enzymology. Preface.

Conn PM.

Methods Enzymol. 2012;506:xxi. doi: 10.1016/B978-0-12-391856-7.00055-X. No abstract available.

PMID:
22341239
34.

Preface.

Conn PM.

Methods Enzymol. 2012;505:xix. doi: 10.1016/B978-0-12-388448-0.00008-5. No abstract available.

PMID:
22289469
35.

Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors.

Conn PM, Ulloa-Aguirre A.

Adv Pharmacol. 2011;62:109-41. doi: 10.1016/B978-0-12-385952-5.00008-7. Review.

36.

Therapeutic rescue of misfolded mutants: validation of primary high throughput screens for identification of pharmacoperone drugs.

Janovick JA, Park BS, Conn PM.

PLoS One. 2011;6(7):e22784. doi: 10.1371/journal.pone.0022784. Epub 2011 Jul 27.

37.

Pharmacoperone identification for therapeutic rescue of misfolded mutant proteins.

Conn PM, Janovick JA.

Front Endocrinol (Lausanne). 2011 Mar 3;2(6). pii: 00006.

38.

Salt bridges overlapping the gonadotropin-releasing hormone receptor agonist binding site reveal a coincidence detector for G protein-coupled receptor activation.

Janovick JA, Pogozheva ID, Mosberg HI, Conn PM.

J Pharmacol Exp Ther. 2011 Aug;338(2):430-42. doi: 10.1124/jpet.111.180869. Epub 2011 Apr 28.

39.

The unfolded protein response and cellular stress, Part C. Preface.

Conn PM.

Methods Enzymol. 2011;491:xix. doi: 10.1016/B978-0-12-385928-0.00028-6. No abstract available.

PMID:
21329790
40.

Biochemical mechanism of pathogenesis of human gonadotropin-releasing hormone receptor mutants Thr104Ile and Tyr108Cys associated with familial hypogonadotropic hypogonadism.

Maya-Núñez G, Janovick JA, Aguilar-Rojas A, Jardón-Valadez E, Leaños-Miranda A, Zariñan T, Ulloa-Aguirre A, Conn PM.

Mol Cell Endocrinol. 2011 Apr 30;337(1-2):16-23. doi: 10.1016/j.mce.2011.01.016. Epub 2011 Jan 26.

41.

Methods in Enzymology. Preface.

Conn PM.

Methods Enzymol. 2011;490:xvii. doi: 10.1016/B978-0-12-385114-7.00020-9. No abstract available.

PMID:
21266240
42.

The unfolded protein response and cellular stress, Part A.. Preface.

Conn PM.

Methods Enzymol. 2011;489:xvii. doi: 10.1016/B978-0-12-385116-1.00020-0. No abstract available.

PMID:
21266220
43.

Use of pharmacoperones to reveal GPCR structural changes associated with constitutive activation and trafficking.

Janovick JA, Conn PM.

Methods Enzymol. 2010;485:277-92. doi: 10.1016/B978-0-12-381296-4.00016-6.

PMID:
21050923
44.

Methods to assess the mechanism of protein function. Preface.

Conn PM.

Methods Enzymol. 2010;484:xxv. doi: 10.1016/B978-0-12-381298-8.00041-1. No abstract available.

PMID:
21036223
45.

The human gonadotropin releasing hormone type I receptor is a functional intracellular GPCR expressed on the nuclear membrane.

Re M, Pampillo M, Savard M, Dubuc C, McArdle CA, Millar RP, Conn PM, Gobeil F Jr, Bhattacharya M, Babwah AV.

PLoS One. 2010 Jul 8;5(7):e11489. doi: 10.1371/journal.pone.0011489.

46.

Dominant negative effects of human follicle-stimulating hormone receptor expression-deficient mutants on wild-type receptor cell surface expression. Rescue of oligomerization-dependent defective receptor expression by using cognate decoys.

Zariñán T, Perez-Solís MA, Maya-Núñez G, Casas-González P, Conn PM, Dias JA, Ulloa-Aguirre A.

Mol Cell Endocrinol. 2010 Jun 10;321(2):112-22. doi: 10.1016/j.mce.2010.02.027. Epub 2010 Mar 4.

47.

Salt bridge integrates GPCR activation with protein trafficking.

Janovick JA, Conn PM.

Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4454-8. doi: 10.1073/pnas.0914261107. Epub 2010 Feb 16.

48.

Ethical research as the target of animal extremism: an international problem.

Conn PM, Rantin FT.

Braz J Med Biol Res. 2010 Feb;43(2):124-6. Epub 2010 Jan 22.

49.

Protein disulfide isomerase chaperone ERP-57 decreases plasma membrane expression of the human GnRH receptor.

Ayala Yáñez R, Conn PM.

Cell Biochem Funct. 2010 Jan;28(1):66-73. doi: 10.1002/cbf.1622.

50.

Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs.

Conn PM, Ulloa-Aguirre A.

Trends Endocrinol Metab. 2010 Mar;21(3):190-7. doi: 10.1016/j.tem.2009.11.003. Epub 2009 Dec 11. Review.

Supplemental Content

Support Center